Fortrea (FTRE) investor relations material

Strategic direction and leadership changes

• Recent acquisition of Worldwide Clinical Trials' clinical pharmacology and bioanalytical business aligns with a strategy to expand core capabilities and reduce reliance on third parties.

• About 25%-30% of senior leaders are new, reflecting a significant management transition and a focus on growth.

• The acquisition adds a 200-bed unit in San Antonio and a bioanalytical lab in Austin, enhancing capacity and operational control.

• The company is shifting from post-spin stabilization to executing on new growth strategies.

• New leadership emphasizes flipping the chapter from restructuring to growth and innovation.

Business model, operations, and market positioning

• Clinical pharmacology is a differentiated, high-margin business, now with five sites and increased capacity for large studies.

• The company is positioned to absorb growth with existing infrastructure, expecting operating leverage as service revenue grows.

• Portfolio diversification is a priority, with a focus on higher-margin clinical pharmacology and FSO, and less emphasis on low-margin FSP.

• Bookings rose nearly 20% in the first half, with a strengthening demand environment and a growing pipeline.

• The company is gaining traction with new clients, including top 30 pharma and emerging biotechs, and expanding internationally, especially in China.

Technology, AI, and innovation

• AI investments are focused on building a robust data layer and integrating intelligence into workflows through the FIT initiative.

• Internal workflow improvements from AI are emerging, but external contracting and pricing changes related to AI are at least a year away.

• FIT is being rolled out module by module, with pilots showing early success among clinical research associates.

• ROI on AI investments is difficult to measure at this stage, but the company is keeping pace with industry peers.

• The approach to AI is philosophical, aiming for long-term integration rather than standalone projects.